?> Thanks a billion as LG Chem broadens deal with Avacta - DirectorsTalk

Be sure to check our sister interview main ratings news website

Thanks a billion as LG Chem broadens deal with Avacta

Avacta Group could earn anything from $1/2bn to $1bn from an extended partnership with LG Chem Life Science, the Massachusetts-based subsidiary of the South Korean LG Group.

The windfall stems from additional drug development programmes utilising Avacta’s Affimer® XT technology.

The foundations were laid in December 2018 when the companies agreed to develop Affimer® therapeutics in several disease areas potentially worth over $300m to Avacta.

Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Avacta Group Plc

More articles like this

Avacta Group Plc

Avacta plc notice regarding publication error

20th January 2021

Regarding a recent aggregated news article published earlier today, which has since been taken down, this was an error on the DirectorsTalk part linking to old news. This was nothing to do with Avacta Plc. The

Avacta Group Plc

Avacta inks radiopharma deal with POINT Biopharma

12th January 2021

UK-based Avacta Group (AIM: AVCT) has entered into a license agreement with Canadian firm POINT Biopharma to provide access to Avacta’s pre|CISION technology for the development of tumor-activated radiopharmaceuticals.  The radiopharmaceutical market is expected to grow

Avacta Group Plc

Avacta signs new cancer therapy deal

8th January 2021

Avacta Group, the developer of innovative cancer therapies, has entered into a license agreement with Point Biopharma to provide access to Avacta’s technology for the development of tumour-activated radiopharmaceuticals. Radiopharmaceutical therapy is now seen as a

Avacta Group Plc

Research looks to improve wastewater testing for COVID-19

5th January 2021

Accurately identifying changes in community COVID-19 infections through wastewater surveillance is moving closer to reality. A new study, published in Environmental Science & Technology, identifies a method that not only detects the virus in wastewater samples but also

Avacta Group Plc

Hopes for clinical trial on humans of tumour targeting drug

29th December 2020

Hopes for clinical trial of tumour targeting drug by Avacta. The company has filed an application for phase one testing, for its pre|CISION prodrug AVA6000. If approved, it will be tested on patients with metastatic solid tumours. The

Avacta Group Plc

BioSpace global roundup

3rd December 2020

U.K.-based Avacta Group announced significant progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral flow test has very good analytical

Avacta Group Plc

Talks could trigger COVID test rollout

27th November 2020

Cambridge biotech Avacta Group is in discussions with commercial partners to establish a route to market for a CE marked BAMS COVID-19 test that can be deployed in hospitals in the UK and Europe. It is

© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.